Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31041102 | 1.00 | KMT2A (0.57) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL3871611 | 1.00 | KMT2A (0.57) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL17751746 | 0.90 | KMT2A (0.55) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL16623132 | 0.90 | KMT2A (0.55) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL26857893 | 0.88 | KMT2A (0.54) | KMT2AEPHX2MDM4TP53CASP3 | |
| SCHEMBL5629775 | 0.88 | KMT2A (0.54) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL5631609 | 0.88 | KMT2A (0.54) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL16702012 | 0.88 | KMT2A (0.49) | KMT2AEPHX2MDM4TP53CASP3 | |
| Hydrochloric Acid SCHEMBL5629777 | 0.87 | KMT2A (0.53) | KMT2AEPHX2CASP3FABP5TLR2 | |
| Hydrochloric Acid SCHEMBL5629771 | 0.87 | KMT2A (0.53) | KMT2AEPHX2CASP3FABP5TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12332246-B2 | Quinoline based cyanine dye turn-on fluorescent probes and methods of use thereof | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-06-17 | — | — | US | disclosed |
| US-11952434-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-09 | — | — | US | disclosed |
| CN-117083088-A | Folate receptor targeted radiotherapy agent and use thereof | 诺华股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-116801900-A | Compounds, compositions and methods of use for treating bone fractures | 普渡研究基金会 | 2023-09-22 | — | — | CN | disclosed |
| EP-3137898-B1 | FLUORESCENT MOLECULAR SENSOR FOR TARGETING CHANGES IN PROTEIN SURFACES, AND METHODS OF USE THEREOF | YEDA RES & DEV (IL) | 2023-09-20 | — | — | EP | disclosed |
| US-11639929-B2 | Universal histidine-tag binding compounds and methods of use thereof as fluorescent probes and sensors | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-05-02 | — | — | US | disclosed |
| US-20230101323-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-30 | — | — | US | disclosed |
| EP-4036575-A1 | QUINOLINE BASED CYANINE DYE TURN-ON FLUORESCENT PROBES AND METHODS OF USE THEREOF | Yeda Research and Development Co. Ltd (IL) | 2022-08-03 | — | — | EP | disclosed |
| CN-114652813-A | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3218392-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3137898-A2 | FLUORESCENT MOLECULAR SENSOR FOR TARGETING CHANGES IN PROTEIN SURFACES, AND METHODS OF USE THEREOF | Yeda Research and Development Co., Ltd. (IL) | 2017-03-08 | — | — | EP | disclosed |
| US-20170045522-A1 | FLUORESCENT MOLECULAR SENSOR FOR TARGETING CHANGES IN PROTEIN SURFACES, AND METHODS OF USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-02-16 | — | — | US | disclosed |
| WO-2016077518-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160137696-A1 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-19 | — | — | US | disclosed |
| WO-2015166491-A2 | FLUORESCENT MOLECULAR SENSOR FOR TARGETING CHANGES IN PROTEIN SURFACES, AND METHODS OF USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-11-05 | — | — | WO | disclosed |
| US-6114328-A | ANTICOAGULANTS; BLOOD DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-09-05 | — | — | US | disclosed |
| US-5849736-A | Isoxazoline and isoxazole fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0832076-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996038426-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952434-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885EPHX2 2816/4885MDM4 672/4885 |
| US-20160137696-A1 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885EPHX2 2816/4885MDM4 672/4885 |
| US-20230101323-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | KMT2A 3513/4885EPHX2 2816/4885MDM4 672/4885 |
| US-11639929-B2 | Universal histidine-tag binding compounds and methods of use thereof as fluorescent probes and sensors | HCLS1, PHF6, PHPT1 | KMT2A 635/4885EPHX2 2591/4885MDM4 64/4885 |
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885EPHX2 2816/4885MDM4 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.